4/15
04:00 pm
arqt
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Low
Report
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
4/14
11:28 pm
arqt
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]
4/8
04:27 pm
arqt
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? [Yahoo! Finance]
Low
Report
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? [Yahoo! Finance]
4/8
03:33 am
arqt
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets [Yahoo! Finance]
Low
Report
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets [Yahoo! Finance]
3/31
04:00 pm
arqt
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Low
Report
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
3/30
06:18 am
arqt
Arcutis Biotherapeutics (ARQT) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Medium
Report
Arcutis Biotherapeutics (ARQT) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
3/28
11:47 am
arqt
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting [Yahoo! Finance]
Low
Report
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting [Yahoo! Finance]
3/28
11:00 am
arqt
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
Low
Report
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
3/23
12:46 am
arqt
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data [Yahoo! Finance]
3/18
05:41 pm
arqt
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children [Yahoo! Finance]
Low
Report
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children [Yahoo! Finance]
3/18
08:00 am
arqt
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
Medium
Report
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
3/10
09:25 am
arqt
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology [Yahoo! Finance]
Low
Report
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology [Yahoo! Finance]
3/10
09:00 am
arqt
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
Low
Report
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
3/6
07:03 pm
arqt
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating [Yahoo! Finance]
Medium
Report
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating [Yahoo! Finance]
3/5
11:25 am
arqt
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]
Low
Report
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]
3/5
09:28 am
arqt
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]
Low
Report
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]
3/5
09:00 am
arqt
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Low
Report
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
3/4
08:22 am
arqt
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]
3/3
08:21 am
arqt
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]
Medium
Report
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]
3/3
08:00 am
arqt
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Medium
Report
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
3/2
08:03 am
arqt
Arcutis Biotherapeutics (ARQT) had its price target lowered by Mizuho from $37.00 to $35.00. They now have an "outperform" rating on the stock.
Medium
Report
Arcutis Biotherapeutics (ARQT) had its price target lowered by Mizuho from $37.00 to $35.00. They now have an "outperform" rating on the stock.
2/27
04:00 pm
arqt
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Medium
Report
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
2/27
11:30 am
arqt
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? [Yahoo! Finance]
Low
Report
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? [Yahoo! Finance]
2/27
10:58 am
arqt
Arcutis Biotherapeutics (ARQT) had its price target raised by Guggenheim from $34.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics (ARQT) had its price target raised by Guggenheim from $34.00 to $35.00. They now have a "buy" rating on the stock.
2/26
12:53 pm
arqt
Arcutis Biotherapeutics (ARQT) had its price target raised by TD Cowen from $30.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Arcutis Biotherapeutics (ARQT) had its price target raised by TD Cowen from $30.00 to $35.00. They now have a "buy" rating on the stock.